Trial Profile
An observational, multi-center, open label study assessing the efficacy and safety of Lucentis (Ranibizumab intravitreal injections) in patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal vein occlusion
- Focus Therapeutic Use
- Sponsors Novartis
- 22 May 2017 Status changed from recruiting to completed.
- 12 Sep 2016 New trial record